A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Single Intramuscular Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Outpatient Treatment of Children with RSV Illness
Participants less than 12 months of age with RSV illness
0 Months - 12 Months
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Jul 2021 by MedImmune, LLC
No locations available
Participants will receive a single IM dose of 30 mg/kg of motavizumab on Day 0 of the study.
A single IM dose of 30 mg/kg will be administered on Day 0 of the study.
Other Name: MEDI-524
|Placebo Comparator: Placebo|
Participants will receive a single IM dose of placebo matched to motavizumab on Day 0 of the study.
A single IM dose of placebo matched to motavizumab will be administered on Day 0 of the study.